Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV T-cell therapy - Benitec/City of Hope

Drug Profile

HIV T-cell therapy - Benitec/City of Hope

Alternative Names: Lentivirus-transduced T-cell immunotherapy; pHIV7-shI-TAR-CCR5RZ treated CD4 cells

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Benitec Biopharma; City of Hope National Medical Center
  • Class Cell therapies; RNA; Small interfering RNA
  • Mechanism of Action Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-0 development in HIV-infections in USA (IV, Infusion)
  • 09 Feb 2011 Development is ongoing in USA
  • 13 Nov 2009 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top